| アブストラクト | INTRODUCTION: Few studies have examined outcomes and potential complications among glaucoma patients who are prescribed topical beta-blockers. This study examined resource usage (number of GP visits and hospitalizations) and diagnoses of respiratory or cardiovascular conditions among glaucoma patients prescribed beta-blockers compared to patients not prescribed beta-blockers. METHODS: A retrospective cohort analysis was conducted using data from the UK Clinical Practice Research Datalink (CPRD) database over the period January 1, 2006 to March 31, 2014. Adult patients with at least one diagnosis of glaucoma were categorized into beta-blocker users and non-beta-blocker users. Beta-blocker users were further separated into patients that maintained beta-blocker therapy and patients that discontinued beta-blocker treatment in year 2 of the post-index period. The CPRD data was queried directly to obtain the number of GP visits, and hospitalizations were extracted by linking the CPRD and Hospital Episode Statistics (HES) patient-level data. RESULTS: In the 12 months after being prescribed beta-blockers, patients that later discontinued beta-blocker treatment had a significantly higher average number of hospitalizations than patients that maintained beta-blocker therapy and the non-beta-blocker users (p < 0.05). In the year after beta-blocker initiation, there was a statistically significant within-group difference pre- and post-beta-blocker initiation for all groups, but the greatest number of GP visits occurred in the patients that subsequently discontinued beta-blocker treatment (mean 19.27). Patients that discontinued beta-blocker treatment were significantly more likely to have cardiovascular events than non-beta-blocker users in the post-index period (p < 0.05). CONCLUSION: This study suggests that the introduction of beta-blockers in a certain group of patients who later discontinue their use is associated with increased use of medical resources (higher number of GP visits and hospitalizations) in glaucoma patients in the UK, which may be indicative of a potential relationship between use of topical beta-blockers in glaucoma therapy and adverse outcomes. |
|---|
| ジャーナル名 | Advances in therapy |
|---|
| Pubmed追加日 | 2017/6/14 |
|---|
| 投稿者 | Viswanathan, Ananth; Spera, Claudio; Mullins, Anmol; Covert, David; Banhazi, Judit; McDwyer, Paul; Hudson, Eibhlin; Ferreira, Alberto |
|---|
| 組織名 | NIHR Biomedical Research Centre, UCL Institute of Ophthalmology, Moorfields Eye;Hospital NHSFT, London, UK.;Novartis Pharma AG, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Novartis Ireland Limited, Dublin, Ireland. judit.banhazi@novartis.com.;Novartis Ireland Limited, Dublin, Ireland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28608143/ |
|---|
